This technology is an organ preservation solution that extends organ viability by preventing glycation.
The shelf-life of organ transplants is limited by tissue swelling and degeneration during storage. Glycation, in which excess sugars bind to proteins or lipids, is one of the main drivers of tissue degeneration. Advanced glycation end products build up and damage tissue structure and mechanical integrity, leading to complications in the transplanted organ’s performance. Although various strategies exist to prolong organ storage, none can effectively prevent glycation during storage.
This technology is a solution for organ preservation that uses modified amino acids found in albumin via site-directed mutagenesis to prevent glycation. Organ preservation solution typically contains albumin, which is known to undergo glycation. Modification of albumin amino acids to inhibit binding with sugars can prevent the formation of harmful advanced glycation end products, better preserving the organ’s physiologic structure and function for transplantation.
